Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous glucagon-like peptide-1 for blood glucose control during enteral feeding in critically ill adults with type 2 diabetes
ACTRN12610000185066Phase 2Completed
- Sponsor
- Adam Deane
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of Glucagon-like peptide 1 in type 2 diabetes mellitus (T2DM) and hyperglycemia (2 arms), sponsored by Adam Deane. Primary endpoint: Blood glucose during small intestinal feeding. Started Jul 2009; status: completed.
02
Drugs
Glucagon-like peptide 1
03
Conditions
type 2 diabetes mellitus (T2DM)hyperglycemia
Beyond the preview
Go deeper on ACTRN12610000185066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000185066.